Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUDSON umbrella study in NSCLC after progression on anti-PD-1/PD-L1 therapy
2023-509004-15-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label trial of durvalumab, ceralasertib, trastuzumab deruxtecan, mycophenolate mofetil and infliximab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Planned start Feb 2018; status: authorised.
02
Drugs
durvalumabceralasertibtrastuzumab deruxtecanmycophenolate mofetilinfliximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509004-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509004-15-00.